The Pharmaceutical Industry

News

Trump eyes Pharma for next round of tariffs

Trump reveals the next industry that will face imminent ‘major’ tariffs

President Donald Trump revealed he will target the pharmaceutical industry with a "major" tariff, citing the majority of the U.S.' pharmaceuticals are made overseas.

Investopedia on MSN · 1d

Pharma Stocks Sink as Trump Says 'Major' Tariffs Coming to Industry

Key Takeaways Shares of several drugmakers fell Wednesday as the threat of tariffs on the industry loomed.President Donald Trump said at an event Tuesday that "a major tariff" was coming to the pharmaceutical industry.

Reuters · 2d

Big Pharma has partial immunity from Trump tariffs

The $1.7 trillion revenue prescription drug industry has a relatively robust immunity to tariffs. Last Wednesday, when U.S. President Donald Trump unveiled a raft of duties on countries and industries he held back on hitting pharmaceuticals.

USA Today7d

Prescription drugs dodge Trump's worldwide tariff for now. What to know.

The pharmaceutical industry isn't celebrating just yet. Trump has mused on multiple occasions that there could be trade actions for the pharmaceutical industry, which has globalized since the ...

1don MSN

Global pharma shares plunge as Trump doubles down on tariff threat

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

Opinion

8dOpinion

The Future of Pharmaceuticals: How Cannabinoids Are Redefining the Industry

In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.

Life sciences companies benefit from the ‘pharma carveout’ in Trump’s tariffs. But how long will it last?

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

STAT11hOpinion

The National Cancer Institute’s Investigational New Drug program is imperative for public good

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results